Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals

Cobb, Bryan PhD1; Pockros, Paul J MD2; Vilchez, Regis A MD, PhD1; Vierling, John M MD3

American Journal of Gastroenterology: April 2013 - Volume 108 - Issue 4 - p 471–475
doi: 10.1038/ajg.2012.248
The Red Section
Buy

Recent regulatory approvals of the NS3/4A protease inhibitors boceprevir and telaprevir launched a new therapeutic era for hepatitis C virus (HCV) genotype 1 infection. Decisions to shorten, extend, or stop treatment with these direct-acting antiviral (DAA) regimens require accurate quantification of serum HCV RNA levels. To effectively use DAA therapies, clinicians must understand performance characteristics of HCV RNA real-time PCR assays and the clinical significance of HCV RNA that is detectable below the lower limit of quantification. This review summarizes terms used to report HCV RNA viral load results, explains the analytical performance of the PCR assay used in the clinical trials of boceprevir and telaprevir, and compares currently available commercial assays.

1 Roche Molecular Systems Inc., Pleasanton, California, USA

2 Division of Gastroenterology and Hepatology, Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, USA

3 Departments of Medicine and Surgery, Baylor College of Medicine, and Liver Center, St Luke's Episcopal Hospital, Houston, Texas, USA

Correspondence: John M. Vierling, MD, Baylor College of Medicine, 1709 Dryden, Suite 1500, Houston, Texas 77030, USA. E-mail: vierling@bcm.tmc.edu

© The American College of Gastroenterology 2013. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website